Cargando…
_version_ 1782249312905854976
author Nakamura, Kazuhiko
Akahoshi, Kazuya
Ochiai, Toshiaki
Komori, Keishi
Haraguchi, Kazuhiro
Tanaka, Munehiro
Nakamura, Norimoto
Tanaka, Yoshimasa
Kakigao, Kana
Ogino, Haruei
Ihara, Eikichi
Akiho, Hirotada
Motomura, Yasuaki
Kabemura, Teppei
Harada, Naohiko
Chijiiwa, Yoshiharu
Ito, Tetsuhide
Takayanagi, Ryoichi
author_facet Nakamura, Kazuhiko
Akahoshi, Kazuya
Ochiai, Toshiaki
Komori, Keishi
Haraguchi, Kazuhiro
Tanaka, Munehiro
Nakamura, Norimoto
Tanaka, Yoshimasa
Kakigao, Kana
Ogino, Haruei
Ihara, Eikichi
Akiho, Hirotada
Motomura, Yasuaki
Kabemura, Teppei
Harada, Naohiko
Chijiiwa, Yoshiharu
Ito, Tetsuhide
Takayanagi, Ryoichi
author_sort Nakamura, Kazuhiko
collection PubMed
description BACKGROUND/AIMS: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. METHODS: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. RESULTS: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. CONCLUSIONS: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.
format Online
Article
Text
id pubmed-3493720
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Pancreatobiliary Association; Korean Society of Gastrointestinal Cancer
record_format MEDLINE/PubMed
spelling pubmed-34937202012-11-20 Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy Nakamura, Kazuhiko Akahoshi, Kazuya Ochiai, Toshiaki Komori, Keishi Haraguchi, Kazuhiro Tanaka, Munehiro Nakamura, Norimoto Tanaka, Yoshimasa Kakigao, Kana Ogino, Haruei Ihara, Eikichi Akiho, Hirotada Motomura, Yasuaki Kabemura, Teppei Harada, Naohiko Chijiiwa, Yoshiharu Ito, Tetsuhide Takayanagi, Ryoichi Gut Liver Original Article BACKGROUND/AIMS: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. METHODS: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. RESULTS: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24±2.41 g/dL) than in the C group (9.44±2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. CONCLUSIONS: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy. The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Pancreatobiliary Association; Korean Society of Gastrointestinal Cancer 2012-10 2012-08-07 /pmc/articles/PMC3493720/ /pubmed/23170144 http://dx.doi.org/10.5009/gnl.2012.6.4.423 Text en Copyright © 2012 by the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Nakamura, Kazuhiko
Akahoshi, Kazuya
Ochiai, Toshiaki
Komori, Keishi
Haraguchi, Kazuhiro
Tanaka, Munehiro
Nakamura, Norimoto
Tanaka, Yoshimasa
Kakigao, Kana
Ogino, Haruei
Ihara, Eikichi
Akiho, Hirotada
Motomura, Yasuaki
Kabemura, Teppei
Harada, Naohiko
Chijiiwa, Yoshiharu
Ito, Tetsuhide
Takayanagi, Ryoichi
Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
title Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
title_full Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
title_fullStr Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
title_full_unstemmed Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
title_short Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
title_sort characteristics of hemorrhagic peptic ulcers in patients receiving antithrombotic/nonsteroidal antiinflammatory drug therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493720/
https://www.ncbi.nlm.nih.gov/pubmed/23170144
http://dx.doi.org/10.5009/gnl.2012.6.4.423
work_keys_str_mv AT nakamurakazuhiko characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT akahoshikazuya characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT ochiaitoshiaki characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT komorikeishi characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT haraguchikazuhiro characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT tanakamunehiro characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT nakamuranorimoto characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT tanakayoshimasa characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT kakigaokana characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT oginoharuei characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT iharaeikichi characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT akihohirotada characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT motomurayasuaki characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT kabemurateppei characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT haradanaohiko characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT chijiiwayoshiharu characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT itotetsuhide characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy
AT takayanagiryoichi characteristicsofhemorrhagicpepticulcersinpatientsreceivingantithromboticnonsteroidalantiinflammatorydrugtherapy